| Design principles for therapeutic angiogenic materials PS Briquez, LE Clegg, MM Martino, FM Gabhann, JA Hubbell Nature Reviews Materials 1 (1), 1-15, 2016 | 174 | 2016 |
| Site-Specific Phosphorylation of VEGFR2 Is Mediated by Receptor Trafficking: Insights from a Computational Model LW Clegg, F Mac Gabhann PLoS Computational Biology 11 (6), 2015 | 65 | 2015 |
| Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes … LE Clegg, RC Penland, S Bachina, DW Boulton, M Thuresson, ... Cardiovascular Diabetology 18, 1-12, 2019 | 62 | 2019 |
| Covalent attachment of a peptide to the surface of gallium nitride MS Makowski, DY Zemlyanov, JA Lindsey, JC Bernhard, EM Hagen, ... Surface science 605 (15-16), 1466-1475, 2011 | 46 | 2011 |
| Molecular mechanism matters: Benefits of mechanistic computational models for drug development LE Clegg, F Mac Gabhann Pharmacological research 99, 149-154, 2015 | 42 | 2015 |
| Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an analysis of … LE Clegg, HJL Heerspink, RC Penland, W Tang, DW Boulton, S Bachina, ... Diabetes Care 42 (2), 318-326, 2019 | 31 | 2019 |
| Systems biology of the microvasculature LE Clegg, F Mac Gabhann Integrative Biology 7 (5), 498-512, 2015 | 29 | 2015 |
| A computational analysis of in vivo VEGFR activation by multiple co-expressed ligands LE Clegg, F Mac Gabhann PLoS computational biology 13 (3), e1005445, 2017 | 27 | 2017 |
| Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial AB van der Aart‐van der Beek, LE Clegg, RC Penland, DW Boulton, ... Diabetes, Obesity and Metabolism 22 (12), 2493-2498, 2020 | 23 | 2020 |
| Systems pharmacology of VEGF165b in peripheral artery disease LE Clegg, VC Ganta, BH Annex, F Mac Gabhann CPT: Pharmacometrics & Systems Pharmacology 6 (12), 833-844, 2017 | 18 | 2017 |
| Prediction and validation of exenatide risk marker effects on progression of renal disease: insights from EXSCEL NMA Idzerda, LE Clegg, AF Hernandez, G Bakris, RC Penland, ... Diabetes, Obesity and Metabolism 22 (5), 798-806, 2020 | 13 | 2020 |
| Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR-TIMI 53 trial) Y Aoki, B Hamrén, LE Clegg, C Stahre, DL Bhatt, I Raz, BM Scirica, ... PLoS One 16 (11), e0259372, 2021 | 9 | 2021 |
| Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 … LE Clegg, Y Jing, RC Penland, DW Boulton, AF Hernandez, RR Holman, ... Diabetes, Obesity and Metabolism 23 (5), 1101-1110, 2021 | 7 | 2021 |
| A computational analysis of pro-angiogenic therapies for peripheral artery disease LE Clegg, F Mac Gabhann Integrative Biology 10 (1), 18-33, 2018 | 5 | 2018 |
| Sparse-grid-based adaptive model predictive control of HL60 cellular differentiation SL Noble, LE Wendel, MM Donahue, GT Buzzard, AE Rundell IEEE transactions on biomedical engineering 59 (2), 456-463, 2011 | 5 | 2011 |
| 394. Consistency of AZD7442 (cilgavimab/tixagevimab) pharmacokinetics across prophylaxis and treatment and adult and pediatric participants: application of population … LE Clegg, O Stepanov, H Schmidt, VP Reddy, W Tang, M Gibbs, S Sedani, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 464, 2023 | 4 | 2023 |
| Arterialized collateral capillaries progress from nonreactive to capable of increasing perfusion in an ischemic arteriolar tree KH Gouin III, SK Hellstrom, LE Clegg, J Cutts, F Mac Gabhann, ... Microcirculation 25 (3), e12438, 2018 | 4 | 2018 |
| 130-LB-Impact of SGLT2 inhibitors (SGLT2i) on cardiovascular (CV) risk and estimated glomerular filtration rate (eGFR) in the EXSCEL placebo group L Clegg, HL Heerspink, RC Penland, T Weifeng, DW Boulton, S Bachina, ... American Diabetes Association scientific meeting, 2018 | 3 | 2018 |
| Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis … LE Clegg, O Stepanov, H Schmidt, W Tang, H Zhang, C Webber, ... Antimicrobial Agents and Chemotherapy 68 (5), e01587-23, 2024 | 2 | 2024 |
| Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group L Clegg, HL Heerspink, RC Penland, W Tang, DW Boulton, S Bachina, ... Diabetes 67 (Supplement_1), 130-LB, 2018 | 2 | 2018 |
